Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7937756 | 1.00 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL287541 | 1.00 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL287542 | 1.00 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL31323920 | 0.98 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL6822770 | 0.98 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL6822769 | 0.98 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL437748 | 0.95 | GRIN2D (0.50) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL288282 | 0.95 | GRIN2D (0.50) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL7935130 | 0.95 | GRIN2D (0.50) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B | |
| SCHEMBL288281 | 0.95 | GRIN2D (0.50) | SLC1A3SLC1A2SLC1A1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197897-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2024-06-20 | — | — | US | claimed |
| US-11970555-B2 | Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1) | BICYCLETX LIMITED (GB) | 2024-04-30 | — | — | US | claimed |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2024-04-04 | — | — | US | claimed |
| US-20240108737-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-04-04 | — | — | US | claimed |
| US-20240083944-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-03-14 | — | — | US | claimed |
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117083287-A | Antiinfective bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2023-11-17 | — | — | CN | claimed |
| EP-4274839-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| EP-4274840-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| EP-4274844-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| US-20210101937-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2021-04-08 | — | — | US | claimed |
| WO-2021064428-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2021-04-08 | — | — | WO | claimed |
| WO-2021019245-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | BICYCLETX LIMITED (GB) | 2021-02-04 | — | — | WO | claimed |
| WO-2021019246-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2021-02-04 | — | — | WO | claimed |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | claimed |
| EP-3678683-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2020-07-15 | — | — | EP | claimed |
| CN-111372942-A | β -catenin function modulating agents and methods thereof | 弗格制药有限公司 | 2020-07-03 | — | — | CN | claimed |
| WO-2020120984-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | BICYCLETX LIMITED (GB) | 2020-06-18 | — | — | WO | claimed |
| WO-2019051327-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2019-03-14 | — | — | WO | claimed |
| CN-108026162-A | Cystine knot scaffold platform | 豪夫迈·罗氏有限公司 | 2018-05-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970555-B2 | Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1) | TFRC, FTH1, SLC40A1 | SLC1A3 715/4885SLC1A2 1039/4885SLC1A1 605/4885 |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | CTNNB1, CTNNBL1, CTNNA1 | SLC1A3 4776/4885SLC1A2 4802/4885SLC1A1 4795/4885 |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | PBK, KLRK1, MICA | SLC1A3 2356/4885SLC1A2 3631/4885SLC1A1 2376/4885 |
| US-20240083944-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | SLC1A3 2575/4885SLC1A2 3520/4885SLC1A1 2813/4885 |
| US-20240197897-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | KLRK1, TIMCC, MICA | SLC1A3 1240/4885SLC1A2 2754/4885SLC1A1 2151/4885 |
| US-20240108737-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | SLC1A3 2575/4885SLC1A2 3520/4885SLC1A1 2813/4885 |
| US-20210101937-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | TIMCC, TAP1, CD81 | SLC1A3 1315/4885SLC1A2 2697/4885SLC1A1 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.